This Article Figures Only Full Text Full Text (PDF) View Current Clinical Collection-Atrial Fibrillation Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Fang, M. C. Search for Related Content PubMed Articles by Fang, M. C. Related Collections Related Articles

FOCUS ISSUE: ATRIAL FIBRILLATION: CLINICAL RESEARCH: ATRIAL FIBRILLATION AND EMBOLISM

Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation

Margaret C. Fang, MD, MPH^_*,_*, Alan S. Go, MD^_*,, Yuchiao Chang, PhD, Leila Borowsky, MPH, Niela K. Pomernacki, RD, Daniel E. Singer, MD for the ATRIA Study Group

^_* Department of Medicine, University of California at San Francisco, San Francisco, California
Division of Research, Kaiser Permanente of Northern California, Oakland, California
Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts.

Manuscript received July 2, 2007; revised manuscript received September 11, 2007, accepted September 17, 2007.

^_* Reprint requests and correspondence: Dr. Margaret C. Fang, 503 Parnassus Avenue, Box 0131, San Francisco, California 94143. (Email: mfang{at}medicine.ucsf.edu).

Objectives: We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)–related thromboembolism in a large community-based cohort.

Background: Risk schemes can help target anticoagulant therapy for patients at highest risk for AF–related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS₂ (Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physicians Guidelines.

Methods: We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identified incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical databases. Each scheme was divided into low, intermediate, and high predicted risk categories and applied to the cohort. Annualized thromboembolism rates and c-statistics (to assess discrimination) were calculated for each risk scheme.

Results: We identified 685 validated thromboembolic events that occurred during 32,721 person-years off warfarin therapy. The risk schemes had only fair discriminating ability, with c-statistics ranging from 0.56 to 0.62. The proportion of patients assigned to individual risk categories varied widely across the schemes. The proportion categorized as low risk ranged from 11.7% to 37.1% across schemes, and the proportion considered high risk ranged from 16.4% to 80.4%.

Conclusions: Current risk schemes have comparable, but only limited, overall ability to predict thromboembolism in persons with AF. Recommendations for antithrombotic therapy may vary widely depending on which scheme is applied for individual patients. Better risk stratification is crucially needed to improve selection of AF patients for anticoagulant therapy.

Abbreviations and Acronyms   ACCP = American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy   AF = atrial fibrillation   AFI = Atrial Fibrillation Investigators   CHADS2 = Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack   CI = confidence interval   ICD-9-CM = International Classification of Diseases-Ninth Revision-Clinical Modification

Related Articles

Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation

William S. Weintraub
J. Am. Coll. Cardiol. 2008 51: 816-817. [Full Text] [PDF]

This article has been cited by other articles:

				A. S. Go, N. Udaltsova, N. K. Pomernacki, M. C. Fang, Y. Chang, L. Borowsky, and D. E. Singer Response to Letter Regarding Article, "Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study" Circulation, November 3, 2009; 120(18): e154 - e154. [Full Text] [PDF]

				N Allou, P Piednoir, C Berroeta, S Provenchere, H Ibrahim, G Baron, P Montravers, B Iung, I Philip, and N Ajzenberg Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin Heart, October 15, 2009; 95(20): 1694 - 1700. [Abstract] [Full Text] [PDF]

				M. M. Sood, P. Komenda, A. R. Sood, C. Rigatto, and J. Bueti The Intersection of Risk and Benefit: Is Warfarin Anticoagulation Suitable for Atrial Fibrillation in Patients on Hemodialysis? Chest, October 1, 2009; 136(4): 1128 - 1133. [Abstract] [Full Text] [PDF]

				D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Ann Intern Med, September 1, 2009; 151(5): 297 - 305. [Abstract] [Full Text] [PDF]

				D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304. [Abstract] [Full Text] [PDF]

				P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF]

				R. G. Hart and L. A. Pearce Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation Stroke, July 1, 2009; 40(7): 2607 - 2610. [Full Text] [PDF]

				A. S. Go The ACTIVE Pursuit of Stroke Prevention in Patients with Atrial Fibrillation N. Engl. J. Med., May 14, 2009; 360(20): 2127 - 2129. [Full Text] [PDF]

				M. H Kim, D. Klingman, J. Lin, P. Pathak, and D. S Battleman Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation Ann. Pharmacother., May 1, 2009; 43(5): 840 - 848. [Abstract] [Full Text] [PDF]

				A. S. Go, M. C. Fang, N. Udaltsova, Y. Chang, N. K. Pomernacki, L. Borowsky, D. E. Singer, and for the ATRIA Study Investigators Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Circulation, March 17, 2009; 119(10): 1363 - 1369. [Abstract] [Full Text] [PDF]

				V. Perera, B. V. Bajorek, S. Matthews, and S. N. Hilmer The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation Age Ageing, March 1, 2009; 38(2): 156 - 162. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				R. Nieuwlaat and S. J Connolly Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes Heart, January 15, 2009; 95(2): 95 - 97. [Full Text] [PDF]

				K. Fatema, K. R. Bailey, G. W. Petty, I. Meissner, M. Osranek, A. A. Alsaileek, B. K. Khandheria, T. S. Tsang, and J. B. Seward Increased Left Atrial Volume Index: Potent Biomarker for First-Ever Ischemic Stroke Mayo Clin. Proc., October 1, 2008; 83(10): 1107 - 1114. [Abstract] [Full Text] [PDF]

				S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin Prevention of stroke in patients with atrial fibrillation: current strategies and future directions Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10. [Abstract] [Full Text] [PDF]

				Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 2008; 39(6): 1901 - 1910. [Abstract] [Full Text] [PDF]

				W. S. Weintraub Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 816 - 817. [Full Text] [PDF]